Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $164.87 USD
Change Today +0.56 / 0.34%
Volume 288.3K
ALXN On Other Exchanges
As of 10:32 AM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

alexion pharmaceuticals inc (ALXN) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/23/15 - $208.88
52 Week Low
09/28/15 - $142.02
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

alexion pharmaceuticals inc (ALXN) Related Businessweek News

View More BusinessWeek News

alexion pharmaceuticals inc (ALXN) Details

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH and aHUS registry; Phase III clinical trials for the treatment of delayed kidney transplant graft function and myasthenia gravis; and Phase II clinical trials for the treatment of antibody mediated rejection in presensitized kidney transplant patients and neuromyelitis optica. In addition, it develops Asfotase alfa, a targeted enzyme replacement therapy that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1007, a novel humanized antibody in Phase II clinical trials for the treatment of anti-phospholipid syndrome and graft versus host disease; and cPMP (ALXN 1101) that is in Phase II trial for treating metabolic disorders. The company primarily serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development and commercialization of Moderna's messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.

2,273 Employees
Last Reported Date: 02/6/15
Founded in 1992

alexion pharmaceuticals inc (ALXN) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $696.1K
Co-Founder, Chairman of The Board and Consult...
Total Annual Compensation: $1.3M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $715.0K
Global Head of Research & Development and Exe...
Total Annual Compensation: $650.0K
Chief Strategy & Portfolio Officer and Execut...
Total Annual Compensation: $325.0K
Compensation as of Fiscal Year 2014.

alexion pharmaceuticals inc (ALXN) Key Developments

Alexion Announces Long-Term Follow-Up Study of Soliris® (eculizumab)

Alexion Pharmaceuticals, Inc. announced that researchers will present data from a long-term follow-up study of the efficacy of Soliris® (eculizumab) in preventing thrombotic microangiopathy (TMA) events in patients with atypical hemolytic uremic syndrome (aHUS). Researchers will also present a post-hoc analysis of the safety of Soliris in pediatric patients with aHUS, as well as an update from the Global aHUS Registry. aHUS is a genetic, chronic, ultra-rare disease associated with vital organ failure and premature death. The data will be presented at the 2015 American Society of Nephrology (ASN) Annual Meeting being held November 3-8, 2015, in San Diego.

Alexion Pharmaceuticals, Inc. Announces Data from the Pivotal Phase 3 ARISE Study

Alexion Pharmaceuticals, Inc. announced that data from the pivotal Phase 3 ARISE study evaluating the safety and efficacy of Kanuma (sebelipase alfa) in children and adults with lysosomal acid lipase deficiency (LAL-D) have been published in the September 10 issue of the New England Journal of Medicine (NEJM). In the study, Kanuma met the primary endpoint of alanine aminotransferase (ALT) normalization compared with placebo (31% vs. 7%, p=0.03) as well as six secondary endpoints. Kanuma is an innovative enzyme replacement therapy that has been approved by the European Commission for the treatment of patients of all ages with LAL-D, a genetic, chronic, and progressive ultra-rare metabolic disease in which infants, children and adults suffer multi-organ damage and premature death. LAL-D is caused by genetic mutations that result in a marked decrease or loss in LAL enzyme activity in the lysosomes across multiple body tissues, leading to the chronic build-up of cholesteryl esters and triglycerides in the liver, blood vessel walls and other tissues. Patients with LAL-D often experience a rapid onset of life-threatening disease manifestations, and many patients may be asymptomatic until they experience a severe consequence of the disease. On September 1, 2015, Alexion announced that the European Commission approved Kanuma for the treatment of patients of all ages with LAL-D. In addition to data from the ARISE study, the summary of product characteristics for Kanuma in the European Union includes clinical data from a separate study showing a significant benefit in terms of survival (67%, or 6 out of 9) in patients with the infant form of LAL-D beyond 12 months, compared with 0 out of 21 patients in an untreated historical cohort.

U.S. Food and Drug Administration Extends the Prescription Drug User Fee Act Date of Alexion Pharmaceuticals, Inc. for its Priority Review of Biologics License Application for Kanuma

Alexion Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for its Priority Review of the company’s Biologics License Application (BLA) for Kanuma (sebelipase alfa), an investigational enzyme replacement therapy for the treatment of lysosomal acid lipase deficiency (LAL-D). The previously disclosed September 8, 2015 PDUFA date has been extended by the standard extension period of three months. In response to a recent request from the FDA, Alexion submitted additional Chemistry, Manufacturing and Controls (CMC) information. Due to the timing of this submission, the FDA extended the PDUFA date to allow additional time for review of the new information. The FDA has not asked for additional clinical data.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALXN:US $164.87 USD +0.56

ALXN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Croda International PLC 2,824 GBp +49.00
Dr Reddy's Laboratories Ltd 4,258 INR +32.65
Sigma-Aldrich Corp $139.59 USD -0.02
Symrise AG €56.70 EUR +0.70
United Therapeutics Corp $124.16 USD -1.12
View Industry Companies

Industry Analysis


Industry Average

Valuation ALXN Industry Range
Price/Earnings 55.8x
Price/Sales 13.8x
Price/Book 4.3x
Price/Cash Flow 62.4x
TEV/Sales 13.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALEXION PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at